IAM Advisory LLC Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

IAM Advisory LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,836 shares of the company’s stock after purchasing an additional 222 shares during the quarter. IAM Advisory LLC’s holdings in Novo Nordisk A/S were worth $1,448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in NVO. Riversedge Advisors LLC grew its position in Novo Nordisk A/S by 7.0% during the fourth quarter. Riversedge Advisors LLC now owns 3,768 shares of the company’s stock valued at $324,000 after buying an additional 245 shares during the period. Ameritas Advisory Services LLC grew its position in shares of Novo Nordisk A/S by 453.3% during the 4th quarter. Ameritas Advisory Services LLC now owns 11,000 shares of the company’s stock valued at $946,000 after acquiring an additional 9,012 shares during the period. HB Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 5.4% during the 4th quarter. HB Wealth Management LLC now owns 17,122 shares of the company’s stock worth $1,473,000 after purchasing an additional 875 shares during the last quarter. Sanibel Captiva Trust Company Inc. raised its holdings in shares of Novo Nordisk A/S by 73.1% in the 4th quarter. Sanibel Captiva Trust Company Inc. now owns 15,568 shares of the company’s stock worth $1,339,000 after purchasing an additional 6,575 shares during the period. Finally, Brooklyn Investment Group raised its holdings in shares of Novo Nordisk A/S by 1,634.3% in the 4th quarter. Brooklyn Investment Group now owns 2,931 shares of the company’s stock worth $252,000 after purchasing an additional 2,762 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 5.2 %

NVO opened at $78.74 on Friday. The firm has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a fifty day moving average price of $97.76 and a 200-day moving average price of $117.23. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.